Scleroderma, Systemic Clinical Trial
Official title:
Light-based Therapy as a Novel Treatment for Digital Ulcers in Patients With Systemic Sclerosis
Digital (finger) ulcers are common in patients with systemic sclerosis (SSc) and causes much
pain and affects how patients use their hands. Our current treatments for digital ulcers are
often not effective and have may have significant side effects (because they increase blood
flow to the ulcer to try and help healing).
Light-based treatment has been successfully used to treat chronic diabetic, pressure and
venous ulcers. The investigators wish to investigate whether light-based treatment is a safe
and effective treatment for digital ulcers in patients with SSc.
Study design This is an open pilot study: all participants will receive the light-based
treatment (visits 1-6 inclusive). Ten participants with at least one digital ulcer (more
than one digital ulcer may be assessed in the study if located on the same hand) will be
recruited.
Justification of sample size There are no pilot data to inform a power calculation. Paired
measurements on 10 participants gives 90% power to detect a clinically meaningful change in
VAS of 2 points at the 5% significance level, provided that the observed standard deviation
in paired differences is 1.7 or less. If the observed standard deviation is 2.0, this sample
size gives 80% power to detect such a change at the stated significance level.
Methods of data collection
Study visits schedule Participants will attend a total of 8 study visits over two months.
Light treatment will be administered twice weekly for three weeks (i.e. the first 6 study
visits only). Follow-up visits will be at 1 month (visit 7) and 2 months (visit 8).
Preparation Participants will be asked to abstain from caffeine-containing drinks and from
smoking for at least 4 hours prior to study. Sterile gauze and/or water may be used by the
investigators (using gloves) to clean the surface of the wound of any debris that could
potentially interfere with the light-based treatment.
Application of the light-based device to the digital ulcer Both the participant and
investigators will wear appropriate safety goggles (as advised by Medical Physics at Salford
Royal NHS Foundation Trust [SRFT]) at all times whilst the light-based device is in
operation. The participant will place their hand within the treatment area of the
light-based device (total treatment area approximately 15cm2), aiming to centralise the
digital ulcer/s to the centre of the treatment region. The device will be controlled by a
custom-built computer interface. At each study visit, the device will undergo a period of
(automatic) calibration before use. All three wavelengths (red, infrared and blue) will be
delivered simultaneously in combination, with the fluence of the device set at [3J/cm2]
(treatment duration approximately 10 to 15 minutes). Performance data on the light-based
treatment (including the total dose delivered and the performance of the LEDs will be
recorded. In the event of catastrophic failure of the device (e.g. failure of multiple
LEDs), the device will automatically shut down.
Participant and investigator assessment of feasibility Participant and the investigators
opinion of the feasibility of light-based treatment will be recorded (at the end of the
first and last treatment study visit).
Participant and investigator assessment of tolerability Participant and investigator opinion
of the tolerability of light-based treatment will be recorded (at the end of the first and
last treatment study visit).
Participant and investigator opinion Participant and investigator global assessments of the
digital ulcer will be performed on a visual analogue scale (0-10, 10 being most severe) at
each study visit. A clinical photograph (see immediately below) will be independently scored
at a later date by another investigator.
Clinical Photography The Clinical Photography department at SRFT will take a photograph of
the digital ulcer/s at the end of each study visit.
High-frequency ultrasound (HFUS) Will be performed immediately by the investigator after the
light-treatment has been delivered and at the follow up visits. The investigator will
perform two 'scans' along the short and long axis of the ulcer and use these to make
measurements (basal and superficial width/length and volume).
Laser Doppler imaging (LDI) Will be performed by the investigator immediately before and
directly after treatment (at the digital ulcer site and the corresponding contralateral arm
position) at all visits to measure ulcer perfusion.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03965780 -
The SPIN - Scleroderma Support Group Leader EDucation Program Trial (SPIN-SSLED)
|
N/A | |
Terminated |
NCT02558543 -
Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis
|
Phase 2 | |
Withdrawn |
NCT01202045 -
Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
|
N/A | |
Terminated |
NCT01445821 -
Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
|
Phase 3 | |
Recruiting |
NCT05878717 -
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
|
Phase 3 | |
Recruiting |
NCT03559465 -
Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis.
|
N/A | |
Not yet recruiting |
NCT03610217 -
Pragmatic Clinical Trials in Scleroderma
|
N/A | |
Completed |
NCT02655640 -
The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis
|
N/A | |
Completed |
NCT05622578 -
Phenotyping of Chronic Pain in Diffused Systemic Scleroderma
|
N/A | |
Recruiting |
NCT04804930 -
Trichoscopy and Systemic Scleroderma
|
||
Completed |
NCT03675581 -
A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
|
Phase 1 | |
Completed |
NCT03221257 -
Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
|
Phase 2 | |
Recruiting |
NCT05559580 -
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
|
Phase 2 | |
Completed |
NCT00442611 -
A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
|
Phase 1/Phase 2 | |
Completed |
NCT00001330 -
Study of Silicone-Associated Connective Tissue Diseases
|
N/A | |
Completed |
NCT02597933 -
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
|
Phase 3 | |
Not yet recruiting |
NCT05821335 -
Leap Motion Based Gamefication Exercises in the Individuals With Systemic Sclerosis
|
N/A | |
Completed |
NCT00333437 -
Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
|
N/A | |
Completed |
NCT00025818 -
Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
|
Phase 3 | |
Not yet recruiting |
NCT05351060 -
Novel Splinting Technique Using 3D Models
|
N/A |